Farmacología clínica de cannabidiol en epilepsias refractarias

Schaiquevich, Paula; Riva, Natalia; Maldonado, Cecilia; Vázquez, Marta; Cáceres-Guido, Paulo.
Farm. hosp ; 44(5): 222-229, sept.-oct. 2020. graf, tab
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-195149

Documentos relacionados

  1. Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.
  2. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
  3. A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam.
  4. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
  5. A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects.
  6. Anti-seizure medications for Lennox-Gastaut syndrome.
  7. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
  8. Clinical pharmacology of cannabidiol in refractory epilepsy.
  9. Pharmacokinetic Drug-Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients.
  10. The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study.